EIS 2024 Programme Outline

EIS 2024
Programme Outline

Open PDF
Sessions will comprise 5 minute talks, plus panel discussion and Q&A. 

12:00 – 12:55

Registration & Networking - Light Lunch

13:00 – 13:10

Opening
Anat Loewenstein, President Euretina
Martin Zinkernagel, General Secretary Euretina

13:10 – 13:40

SESSION 1
Nonneovascular AMD and IRDs
Moderators: Kourous Rezaei / Frank Holz

13:10     Cedric FrancoisApellis
Committed to Saving Retina and Preserving Function in GA

13:15     Sharon Bakalash, Astellas
Revealing the Master Key: Unlocking Success in the Treatment of Geographic Atrophy

13:20     Tarek Hassan, Aviceda
Glycoimmunology in the Management of Geographic Atrophy from AMD

13:25     David Zacks, ONL Therapeutics
Targeting Fas Pathway: ONL Therapeutics’ Approach to Dry AMD

13:30     Panel Discussion             
Kourous Rezaei, Frank Holz, Cedric Francois, Sharon Bakalash, Tarek Hassan & David Zacks  

13:45 – 14:25

SESSION 2
VEGF related and other retinal indications
Moderators: Anat Loewenstein / Francesco Bandello

13:45     Sascha Fauser, Roche
Roche’s Commitment to Ophthalmology – Building an Innovative Pipeline

13:50     Julian Smith, Abbvie
A Commitment to Addressing Unmet Needs in Retinal Diseases

13:55     Jennifer Kissner, Outlook Therapeutics  
Redefining the Standard of Care for Bevacizumab as an Anti VEGF for Retina

14:00     Ramiro Ribeiro, Eyepoint Pharmaceuticals 
Committed to Developing Therapeutics to Help Improve the Lives of Patients with Serious Retinal Diseases

14:05     Nadia K Waheed, Ocular Therapeutix
Changing the Future Paradigm for the Management of Retinal Vascular Diseases

14:10     Star Seyedkazemi, Adverum Biotech
Ixo-vec: Addressing the Unmet Needs in Wet AMD Treatment

14:15     Panel Discussion  
Anat Loewenstein, Francesco Bandello, Sascha Fauser, Julian Smith, Jennifer Kissner, Ramiro Ribeiro & Nadia K. Waheed

14:30 – 15:00

SESSION 3
Nonneovascular AMD and IRDs
Moderators: Kourous Rezaei / Frank Holz

14:30     Remko Bakker, Boehringer Ingelheim 
Driving Innovation Beyond Anti-VEGF

14:35     Sam Barone, Nanoscope Therapeutics  
Breakthrough in Vision Restoration: Mutation-agnostic Optogenetics for Inherited Retinal Diseases and Geographic atrophies

14:40     Ralf Hornig, SCIENCE 
The PRIMA Retinal Implant for Patients with Geographic Atrophy

14:45     Kirsten Vonde, Granzer Regulatory Consulting & Services 
Development and Regulatory Thoughts for Gene Therapies in AMD

14:50     Panel Discussion 
Kourous Rezaei, Frank Holz, Remko Bakker, Sam Barone, Ralf Hornig & Kirsten Vonde

15:05 – 15:30

SESSION 4
Investor Panel
Moderators: Anat Loewenstein / Kourous Rezaei

Round Table Discussion: Anta Gkelou/SOFINNOVA PARTNERS, Edward Van Wezel/ BIOGENERATION VENTURES, Bonnie van Wilgenburg/MONOGRAPH BIO

15:30 – 16:00

NETWORKING BREAK 

16:00 – 16:35

SESSION 5
VEGF related and other retinal indications
Moderators: Anat Loewenstein / Francesco Bandello

16:00     Sergio Leal, Bayer 
Bayer’s Vision for the Future of Ophthalmology

16:05     Riad Sherif, Oculis  
OCS-01, an OPTIREACH® Formulation of High Concentration Dexamethasone Eye Drop, for the Treatment of DME

16:10     Frederic Guerard, Opthea  
Sozinibercept in Wet AMD: Potential for Superior Vision Outcomes Beyond Anti-VEGF-A Therapies

16:15     Robert Kim, 4D Molecular Therapeutics 
4D Molecular Therapeutics: New Era of Genetic Medicine

16:20     Sumie Takahara, Regenxbio  
Innovation to Address Unmet Needs in Retinal Diseases

16:25     Panel Discussion 
Anat Loewenstein, Francesco Bandello, Sergio Leal, Riad Sherif, Frederic Guerard, Robert Kim & Sumie Takahara

16:40 – 17:25

SESSION 6
Innovations in Retinal Surgery, Imaging, and AI
Moderators: Alistair Laidlaw / Tunde Peto

16:40     Stephanie Magazzeni, Zeiss 
Workflows, Imaging & AI: ZEISS Game Changers from the Office to the OR

16:45     Derek Swan, Optos  
Recent Advances in Multimodal Ultrawidefield Retinal Imaging

16:50     Dimitris Aktypis, Alcon  
Alcon – Innovation Lights the path to sight

16:55     Pierre Billardon, DORC 
Clinically Relevant Innovation in Retina Surgery

17:00     Helge Menz, Pharmpur 
Let There be Light – Challenges and Solutions

17:05     Carlos Ciller, Retinai 
Transforming Healthcare: Unlocking the Power of Data to Improve R&D and Patient Outcomes

17:10     Panel Discussion 
Alistair Laidlaw, Tunde Peto, Stephanie Magazzeni, Derek Swan, Dimitris Aktypis, Pierre Billardon, Helege Menz, Carlos Ciller, Grazia Pertile & Stela Vujosevic

17:30 – 17:51

SESSION 7
Rapid Fire Panel Discussion
Moderators: Martin Zinkernagel / Arshad Khanani

17:30     Stephanie Campbell, Okko Health 
Proactive Disease Management Using Smartphone Self-Monitoring

17:33     Kester Nahen, Notal Vision 
SCANLY Home OCT Monitoring Program – A New Patient Management Paradigm

17:36     Ioanna Psalti, EU EYE
EUEYE: from Bench to Bedside to Policy Innovation and Back

17:39     Amir Sadeghipour, Retinsight 
Revealing the Invisible: An automated GA Monitor Enhances Diagnostic Efficacy

17:42     Manuel Opitz, deepeye Medical GmbH 
From “treat & extend” to “predict & treat”: The AI Co-pilot for Anti-VEGF Treatment in Busy Clinics to Drive Outcomes & Adherence

17:45     Christian Roesky, Novaliq 
Novaliq’s Water-Free Eye Drops: A New Treatment Paradigm for Diabetic Retinopathy

17:48     Brad Doerschuk, InFocus Clinical Research  
Enhancing Clinical Trials with Real-Time Intelligence (RTI): A Revolutionary Approach

17:51 – 17:56

Closing Remarks
Nicole Eter

17:56

Networking - Drinks & Canapes

12:00 – 12:55

Registration & Networking - Light Lunch

13:00 – 13:10

Opening
Anat Loewenstein, President Euretina
Martin Zinkernagel, General Secretary Euretina

13:10 – 13:40

SESSION 1
Nonneovascular AMD and IRDs
Moderators: Kourous Rezaei / Frank Holz

13:10     Cedric FrancoisApellis
Committed to Saving Retina and Preserving Function in GA

13:15     Sharon Bakalash, Astellas
Revealing the Master Key: Unlocking Success in the Treatment of Geographic Atrophy

13:20     Tarek Hassan, Aviceda
Glycoimmunology in the Management of Geographic Atrophy from AMD

13:25     David Zacks, ONL Therapeutics
Targeting Fas Pathway: ONL Therapeutics’ Approach to Dry AMD

13:30     Panel Discussion             
Kourous Rezaei, Frank Holz, Cedric Francois, Sharon Bakalash, Tarek Hassan & David Zacks

13:45 – 14:25

SESSION 2
VEGF related and other retinal indications
Moderators: Anat Loewenstein / Francesco Bandello

13:45     Sascha Fauser, Roche
Roche’s Commitment to Ophthalmology – Building an Innovative Pipeline

13:50     Julian Smith, Abbvie
A Commitment to Addressing Unmet Needs in Retinal Diseases

13:55     Jennifer Kissner, Outlook Therapeutics  
Redefining the Standard of Care for Bevacizumab as an Anti VEGF for Retina

14:00     Ramiro Ribeiro, Eyepoint Pharmaceuticals 
Committed to Developing Therapeutics to Help Improve the Lives of Patients with Serious Retinal Diseases

14:05     Nadia K Waheed, Ocular Therapeutix   
Changing the Future Paradigm for the Management of Retinal Vascular Diseases

14:10     Star Seyedkazemi, Adverum Biotech  
Ixo-vec: Addressing the Unmet Needs in wet AMD Treatment

14:15     Panel Discussion  
Anat Loewenstein, Francesco Bandello, Sascha Fauser, Julian Smith, Jennifer Kissner, Ramiro Ribeiro & Nadia K. Waheed

14:30 – 15:00

SESSION 3
Nonneovascular AMD and IRDs
Moderators: Kourous Rezaei / Frank Holz

14:30     Remko Bakker, Boehringer Ingelheim 
Driving Innovation Beyond Anti-VEGF

14:35     Sam Barone, Nanoscope Therapeutics  
Breakthrough in Vision Restoration: Mutation-agnostic Optogenetics for Inherited Retinal Diseases and Geographic atrophies

14:40     Ralf Hornig, SCIENCE 
The PRIMA Retinal Implant for Patients with Geographic Atrophy

14:45     Kirsten Vonde, Granzer Regulatory Consulting & Services 
Development and Regulatory Thoughts for Gene Therapies in AMD

14:50     Panel Discussion 
Kourous Rezaei, Frank Holz, Remko Bakker, Sam Barone, Ralf Hornig & Kirsten Vonde

15:05 – 15:30

SESSION 4
Investor Panel
Moderators: Anat Loewenstein / Kourous Rezaei

Round Table Discussion: Anta Gkelou/SOFINNOVA PARTNERS, Edward Van Wezel/ BIOGENERATION VENTURES, Bonnie van Wilgenburg/MONOGRAPH BIO

15:30 – 16:00

NETWORKING BREAK

16:00 – 16:35

SESSION 5
VEGF related and other retinal indications
Moderators: Anat Loewenstein / Francesco Bandello

16:00     Sergio Leal, Bayer 
Bayer’s Vision for the Future of Ophthalmology

16:05     Riad Sherif, Oculis  
OCS-01, an OPTIREACH® Formulation of High Concentration Dexamethasone Eye Drop, for the Treatment of DME

16:10     Frederic Guerard, Opthea  
Sozinibercept in Wet AMD: Potential for Superior Vision Outcomes Beyond Anti-VEGF-A Therapies

16:15     Robert Kim, 4D Molecular Therapeutics 
4D Molecular Therapeutics: New Era of Genetic Medicine

16:20     Sumie Takahara, Regenxbio  
Innovation to Address Unmet Needs in Retinal Diseases

16:25     Panel Discussion 
Anat Loewenstein, Francesco Bandello, Sergio Leal, Riad Sherif, Frederic Guerard, Robert Kim & Sumie Takahara

16:40 – 17:25

SESSION 6
Innovations in Retinal Surgery, Imaging, and AI
Moderators: Alistair Laidlaw / Tunde Peto

16:40     Stephanie Magazzeni, Zeiss 
Workflows, Imaging & AI: ZEISS Game Changers from the Office to the OR

16:45     Derek Swan, Optos  
Recent Advances in Multimodal Ultrawidefield Retinal Imaging

16:50     Dimitris Aktypis, Alcon  
Alcon – Innovation Lights the Path to Sight

16:55     Pierre Billardon, DORC 
Clinically Relevant Innovation in Retina Surgery

17:00     Helge Menz, Pharmpur 
Let There be Light – Challenges and Solutions

17:05     Carlos Ciller, Retinai 
Transforming Healthcare: Unlocking the Power of Data to Improve R&D and Patient Outcomes

17:10     Panel Discussion 
Alistair Laidlaw, Tunde Peto, Stephanie Magazzeni, Derek Swan, Dimitris Aktypis, Pierre Billardon, Helege Menz, Carlos Ciller, Grazia Pertile & Stela Vujosevic

17:30 – 17:51

SESSION 7
Rapid Fire Panel Discussion
Moderators: Martin Zinkernagel / Arshad Khanani

17:30     Stephanie Campbell, Okko Health 
Proactive Disease Management Using Smartphone Self-Monitoring

17:33     Kester Nahen, Notal Vision 
SCANLY Home OCT Monitoring Program – A New Patient Management Paradigm

17:36     Ioanna Psalti, EU EYE
EUEYE: from Bench to Bedside to Policy Innovation and Back

17:39     Amir Sadeghipour, Retinsight 
Revealing the Invisible: An automated GA Monitor Enhances Diagnostic Efficacy

17:42     Manuel Opitz, deepeye Medical GmbH 
From “treat & extend” to “predict & treat”: The AI Co-pilot for Anti-VEGF Treatment in Busy Clinics to Drive Outcomes & Adherence

17:45     Christian Roesky, Novaliq 
Novaliq’s Water-Free Eye Drops: A New Treatment Paradigm for Diabetic Retinopathy

17:48     Brad Doerschuk, InFocus Clinical Research  
Enhancing Clinical Trials with Real-Time Intelligence (RTI): A Revolutionary Approach

17:51 – 17:56

Closing Remarks
Nicole Eter

17:56

Networking - Drinks & light canapes

Please note, this programme may be subject to change.